CVR number 36476834
Industry 86.9020 Other human health activities

IKAST FYSIOTERAPI I ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Loading...
Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  3.2% 6.3% 5.2% 3.9% 2.5%  
Credit score (0-100)  57 37 41 50 62  
Credit rating  BBB BBB BBB BBB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales  542 519 1,067 1,205 1,110  
Gross profit  531 507 1,054 1,184 1,097  
EBITDA  531 507 1,054 1,184 1,097  
EBIT  531 507 1,054 1,184 1,097  
Pre-tax profit (PTP)  527.5 503.6 1,050.4 1,189.4 1,135.1  
Net earnings  410.7 392.1 818.3 927.3 885.4  
Pre-tax profit without non-rec. items  527 504 1,050 1,189 1,135  
 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  940 442 960 1,288 1,473  
Interest-bearing liabilities  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  1,020 550 1,230 1,571 1,759  
Net Debt  -7.1 -13.7 -1.5 -0.0 0.0  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales  542 519 1,067 1,205 1,110  
Net sales growth  23.4% -4.3% 105.6% 13.0% -7.9%  
Gross profit  531 507 1,054 1,184 1,097  
Gross profit growth  23.8% -4.5% 108.1% 12.3% -7.3%  
Employees  1 1 1 1 1  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  1,020 550 1,230 1,571 1,759  
Balance sheet change%  -2.6% -46.1% 123.7% 27.7% 12.0%  
Added value  530.6 506.8 1,054.5 1,183.8 1,097.3  
Added value %  97.8% 97.7% 98.9% 98.2% 98.8%  
Investments  0 0 0 0 0  
Net sales trend  1.0 -1.0 1.0 2.0 -1.0  
EBIT trend  4.0 5.0 5.0 5.0 5.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  97.8% 97.7% 98.9% 98.2% 98.8%  
EBIT %  97.8% 97.7% 98.9% 98.2% 98.8%  
EBIT to gross profit (%)  100.0% 100.0% 100.0% 100.0% 100.0%  
Net Earnings %  75.7% 75.6% 76.7% 76.9% 79.8%  
Profit before depreciation and extraordinary items %  75.7% 75.6% 76.7% 76.9% 79.8%  
Pre tax profit less extraordinaries %  97.3% 97.1% 98.5% 98.7% 102.2%  
ROA %  51.3% 64.5% 118.5% 85.0% 68.2%  
ROI %  55.7% 70.6% 146.9% 105.4% 81.1%  
ROE %  55.9% 56.7% 116.7% 82.5% 64.1%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  92.2% 80.4% 78.1% 82.0% 83.7%  
Relative indebtedness %  9.0% 16.5% 24.3% 23.5% 22.3%  
Relative net indebtedness %  7.7% 13.9% 24.2% 23.5% 22.3%  
Net int. bear. debt to EBITDA, %  -1.3% -2.7% -0.1% -0.0% 0.0%  
Gearing %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  1.5% 0.0% 0.0% 0.0% 0.0%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.1 0.2 1.8 2.6 2.6  
Current Ratio  0.1 0.2 1.8 2.6 2.6  
Cash and cash equivalent  7.1 13.7 1.5 0.0 0.0  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 106.1 177.6  
Current assets / Net sales %  1.3% 2.6% 43.7% 61.8% 58.5%  
Net working capital  -41.7 -72.0 207.1 462.1 402.3  
Net working capital %  -7.7% -13.9% 19.4% 38.3% 36.2%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  542 519 1,067 1,205 1,110  
Added value / employee  531 507 1,054 1,184 1,097  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  531 507 1,054 1,184 1,097  
EBIT / employee  531 507 1,054 1,184 1,097  
Net earnings / employee  411 392 818 927 885